Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

117 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Among authors: slakter js. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
Anecortave acetate (15 milligrams) versus photodynamic therapy for treatment of subfoveal neovascularization in age-related macular degeneration.
Slakter JS, Bochow TW, D'Amico DJ, Marks B, Jerdan J, Sullivan EK, Robertson SM, Slakter JS, Sullins G, Zilliox P; Anecortave Acetate Clinical Study Group. Slakter JS, et al. Ophthalmology. 2006 Jan;113(1):3-13. doi: 10.1016/j.ophtha.2005.10.019. Epub 2005 Dec 20. Ophthalmology. 2006. PMID: 16368146 Clinical Trial.
Characterizing New-Onset Exudation in the Randomized Phase 2 FILLY Trial of Complement Inhibitor Pegcetacoplan for Geographic Atrophy.
Wykoff CC, Rosenfeld PJ, Waheed NK, Singh RP, Ronca N, Slakter JS, Staurenghi G, Monés J, Baumal CR, Saroj N, Metlapally R, Ribeiro R. Wykoff CC, et al. Among authors: slakter js. Ophthalmology. 2021 Sep;128(9):1325-1336. doi: 10.1016/j.ophtha.2021.02.025. Epub 2021 Mar 10. Ophthalmology. 2021. PMID: 33711380 Free article. Clinical Trial.
Safety and Efficacy of Subretinally Administered Palucorcel for Geographic Atrophy of Age-Related Macular Degeneration: Phase 2b Study.
Heier JS, Ho AC, Samuel MA, Chang T, Riemann CD, Kitchens JW, Slakter JS, Leiderman YI, Spencer R, Williams GA, Hickson-Curran SB, Keane M, Baldassarre JS; Prelude Study Group. Heier JS, et al. Among authors: slakter js. Ophthalmol Retina. 2020 Apr;4(4):384-393. doi: 10.1016/j.oret.2019.11.011. Epub 2019 Nov 19. Ophthalmol Retina. 2020. PMID: 32033908 Clinical Trial.
Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular Degeneration: A Randomized Phase 2 Trial.
Liao DS, Grossi FV, El Mehdi D, Gerber MR, Brown DM, Heier JS, Wykoff CC, Singerman LJ, Abraham P, Grassmann F, Nuernberg P, Weber BHF, Deschatelets P, Kim RY, Chung CY, Ribeiro RM, Hamdani M, Rosenfeld PJ, Boyer DS, Slakter JS, Francois CG. Liao DS, et al. Among authors: slakter js. Ophthalmology. 2020 Feb;127(2):186-195. doi: 10.1016/j.ophtha.2019.07.011. Epub 2019 Jul 16. Ophthalmology. 2020. PMID: 31474439 Free article. Clinical Trial.
Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers.
Ackert J, Mohamed K, Slakter JS, El-Harazi S, Berni A, Gevorkyan H, Hardaker E, Hussaini A, Jones SW, Koh GCKW, Patel J, Rasmussen S, Kelly DS, Barañano DE, Thompson JT, Warren KA, Sergott RC, Tonkyn J, Wolstenholme A, Coleman H, Yuan A, Duparc S, Green JA. Ackert J, et al. Among authors: slakter js. Drug Saf. 2019 Sep;42(9):1103-1114. doi: 10.1007/s40264-019-00839-w. Drug Saf. 2019. PMID: 31187437 Free PMC article. Clinical Trial.
Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
Lanzetta P, Cruess AF, Cohen SY, Slakter JS, Katz T, Sowade O, Zeitz O, Ahlers C, Mitchell P. Lanzetta P, et al. Among authors: slakter js. Acta Ophthalmol. 2018 Dec;96(8):e911-e918. doi: 10.1111/aos.13751. Epub 2018 Apr 16. Acta Ophthalmol. 2018. PMID: 29659183 Free article. Clinical Trial.
117 results